Short communicationVaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS)
Introduction
In the United States, two kinds of hepatitis B vaccines (HBV) have been produced and distributed. Plasma-derived HBV are no longer manufactured in the United States; all current HBV are produced by recombinant methods [1]. Modern genetically engineered HBV are highly effective and safe products [2]. They are prepared by harvesting hepatitis B surface antigen from cell cultures of recombinant strains of Saccharomyces cerevisiae (common bakers’ yeast) that carry the surface antigen gene of hepatitis B virus. As a result of biochemical and biophysical purification, there is no detectible yeast DNA and only trace amounts of yeast proteins (1–5%) in the final vaccine products [3], [4], [5], [6], [7]. Two polysaccharide vaccines, HibTITER and Prevnar, include a conjugating protein (CRM197) isolated from cultures of Corynebacterium diphtheriae grown in a yeast extract-based medium. However, the final vaccine products do not contain yeast protein [8], [9]. Whether these residual yeast proteins in HBV could act as antigens or allergens in vaccinees was evaluated early in vaccine development. To address this issue, testing for both IgG and IgE antibodies against yeast proteins were performed in small subsets (50–133 subjects) of volunteers participating in clinical trials [10], [11], [12]. Hundred percent of subjects had IgG antibodies against yeast even before vaccination, presumably due to prior exposure by, for example, eating bread. The titers of these IgG antibodies rose, fell, or remained unchanged after immunization, but showed no consistent pattern and were not related to any clinical complaints after vaccination. 1–2% of subjects had anti-yeast antibodies of the IgE class even prior to immunization, but received the vaccine uneventfully and had no significant rise in the titer of these antibodies. It was concluded from these studies that the small amounts of yeast proteins in recombinant HBV do not provoke immune reactions in vaccine recipients or cause allergic reactions in the rare subjects with pre-existing anti-yeast IgE antibodies. Further, IgE-mediated allergy to yeast as an aeroallergen or food allergen is actually quite rare, although it may have some immunologic cross-reactivity with other fungi [13], [14], [15]. In a study of 193 bakery workers, including 104 filing claims for baker's asthma, none had positive skin tests to baker's yeast [15]. A potentially confounding circumstance is the belief by some patients and practitioners in the “yeast hypersensitivity syndrome” [16]. In this “syndrome,” a wide range of ill-defined symptoms is attributed to exposure to the yeast, Candida albicans. This organism is actually part of normal human flora, and the condition lacks biologic plausibility and has been deemed unproven. Patients who believe they suffer from this malady may think of themselves as “allergic to yeast”, but even the proponents of this entity do not claim it is IgE mediated or causes anaphylaxis. Nonetheless, hypersensitivity to yeast is listed in HBV package inserts as a contraindication for HBV administration [4], [5], [6], [7], [8].
In the US, a nationwide post-marketing monitoring system for vaccine safety known as the vaccine adverse event reporting system (VAERS) has been in place since 1990. The goal of this review was to find if adverse events (AE) have been reported to VAERS following vaccination of individuals reportedly allergic to yeast. We were particularly interested in identifying and describing possible IgE-mediated anaphylactic reactions.
Section snippets
Methods
VAERS is a spontaneous reporting system for adverse events following vaccination with US licensed vaccines that is maintained by the U.S. Department of Health and Human Services [17], [18]. VAERS accepts AE reports from vaccine providers, other healthcare workers, vaccinees or their parents, and other reporters, either directly or via vaccine manufacturers. The VAERS form provides space for comments regarding the vaccinee's pre-existing physician-diagnosed allergies and other medical conditions
Results
From July 1, 1990 through July 1, 2004, there were 180,895 adverse event reports submitted to VAERS. Additionally, the Centers for Disease Control and Prevention biologics surveillance data from 1991–2001 indicate a distribution of more than 276 million doses of HBV in the United States [18]. Among VAERS reports, we identified 107 reports that mentioned a history of allergy to yeast that was present prior to vaccination and occurrence of adverse symptoms. Eighty-two of these 107 reports
Discussion
Reviews of post-marketing experience with recombinant HBV have confirmed a favorable safety profile for these vaccines [21], [22], [23]. Cases and case-series of various severe adverse reactions occurring in temporal association with HBV have been described in the literature. Some of them, e.g. neurological and autoimmune conditions, have caused controversy; however, the consensus today is that even if some of these reactions are causally related to HBV, the rate of these reactions is very
References (32)
Clinical experience with hepatitis B vaccines
Am J Infect Control
(1989)- et al.
Baker's asthma caused by Saccharomyces cerevisiae in dry powder form
J Allergy Clin Immunol
(1996) - et al.
Baker's asthma: still among the most frequent occupational respiratory disorders
J Allergy Clin Immunol
(1998) - et al.
The Vaccine Adverse Event Reporting System (VAERS)
Vaccine
(1994) - et al.
Symposium on the definition and management of anaphylaxis: summary report
J Allergy Clin Immunol
(2005) - et al.
Major adverse reactions to yeast-derived hepatitis B vaccines—a review
Vaccine
(1998) - et al.
Post-marketing evaluation of the short term safety of COMVAX
Vaccine
(2004) - et al.
Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization
J Allergy Clin Immunol
(2004) - et al.
Yeast-derived hepatitis B vaccine and yeast sensitivity
Lancet
(1989) - et al.
Adverse reaction to the recombinant hepatitis B vaccine
J Allergy Clin Immunol
(1991)
Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS)
Vaccine
The gelatin story
J Allergy Clin Immunol
Safety of immunisation and adverse events following vaccination against hepatitis B
Exp Opin Drug Saf
Cited by (0)
- 1
Co-corresponding author.
- 2
Present address: Meningitis and Special Pathogens Branch, NCID/CDC, Mail Stop C09, Atlanta, GA 30333, USA.